                         SEQUENCE LISTING

<110>  Yeda Research and Development Co. Ltd.
       ROTTER, Varda
       OREN, Moshe
       TAL, Perry
       ALBERICIO, Fernando
 
<120>  PEPTIDE ANALOGS AND USE OF SAME IN TREATING DISEASES, DISORDERS 
       OR CONDITIONS ASSOCIATED WITH A MUTANT p53 PROTEIN

<130>  QNT003PCT

<150>  US 62/990,017
<151>  2020-03-16

<160>  73    

<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  misc_feature
<222>  (1)..(1)
<223>  may be conjugated to a hydrophobic moiety selected from the group
       consisting of palmitoyl (C16); phtanoyl ((CH3)4); heptadecanoyl 
       (C17); stearoyl (C18) and nonadecanoyl (C19)

<220>
<221>  misc_feature
<222>  (1)..(9)
<223>  may be cyclized ( between side chain to the C terminus)

<220>
<221>  misc_feature
<222>  (1)..(9)
<223>  may have a targeting moiety

<220>
<221>  misc_feature
<222>  (5)..(5)
<223>  X  can be any amino acid

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  X is selected from the group consisting of D-Proline, Dab, 
       L-Proline, Dmp, DMP and  tic

<220>
<221>  misc_feature
<222>  (7)..(7)
<223>  X is   Diaminobutyric Acid (DAB)

<400>  1

Arg Arg His Ser Xaa Xaa Xaa Pro Asp 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group attached

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is L- Diaminobutyric Acid (L-DAB)

<400>  2

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Palmitic acid  conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  3

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  4
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Arachidic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  4

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  5
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Behenic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  5

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  6
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D-proline

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  6

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  7
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is (S)-(-)-Indoline-2-carboxylic acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  7

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  8
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is Pipecolic acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  8

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is octahydroindolecarboxylic acid(Oic)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  9

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  10
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is 4-tetrahydroisoquinoline-3-carboxylic acid (Tic)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  10

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  11
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  misc_feature
<222>  (1)..(9)
<223>  Cyclization of Lysine side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  11

Arg Arg His Ser Lys Pro Xaa Pro Asp 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  misc_feature
<222>  (1)..(9)
<223>  Cyclization of Lysine side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  12

Arg Arg Lys Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  13
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  misc_feature
<222>  (1)..(10)
<223>  Cyclization of Lysine side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  13

Arg Arg Lys His Ser Val Pro Xaa Pro Asp 
1               5                   10  


<210>  14
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is  Di-methyl proline (Dmp)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  14

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  15

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  16

<400>  16
000

<210>  17
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- lysine

<220>
<221>  misc_feature
<222>  (6)..(6)
<223>  x is 4-tetrahydroisoquinoline-3-carboxylic acid (Tic)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  17

Arg Arg His Ser Lys Xaa Xaa Pro Asp 
1               5                   


<210>  18
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D- Proline

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  18

Arg Arg His Ser Val Pro Xaa Pro Asp Gly Glu Ala 
1               5                   10          


<210>  19
<211>  11
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D- Proline

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  19

Arg Arg His Ser Val Pro Xaa Pro Asp Gly Arg 
1               5                   10      


<210>  20
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  20

Asp Pro His Val Ser Pro Arg Xaa Arg 
1               5                   


<210>  21
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  21

Arg Asp Pro His Val Ser Pro Arg Xaa 
1               5                   


<210>  22
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (1)..(9)
<223>  Cyclization of Lysine side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Lysine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D- Proline

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  22

Arg Arg His Ser Lys Pro Xaa Pro Asp 
1               5                   


<210>  23
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (1)..(9)
<223>  Cyclization of Lysine side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  23

Asp Pro His Lys Ser Pro Arg Xaa Arg 
1               5                   


<210>  24
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  24

Arg Arg His Ser Thr Pro His Pro Asp 
1               5                   


<210>  25
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X is  alpha-aminoisobutyric acid

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  25

Arg Arg His Ser Thr Xaa His Ala Asp 
1               5                   


<210>  26
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<400>  26

Asp Pro His Thr Ser Pro Arg His Arg 
1               5                   


<210>  27
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  27

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  28
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Stearic acid conjugated

<220>
<221>  MISC_FEATURE
<222>  (1)..(9)
<223>  Cyclization of Dab side chain to C terminal carboxyl

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  28

Arg Arg His Ser Xaa Pro Xaa Pro Asp 
1               5                   


<210>  29
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  29

Arg Arg His Ser Glu Pro Xaa Pro Asp His 
1               5                   10  


<210>  30
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  30

Arg Arg His Ser Glu Pro Xaa Pro Ala His 
1               5                   10  


<210>  31
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  X is  alpha-aminoisobutyric acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<400>  31

Arg Arg His Ser Val Xaa Xaa Pro Asp 
1               5                   


<210>  32
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  32

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  33
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  33

Arg Ala His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  34
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  34

Arg Arg Ala Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  35
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  35

Arg Arg His Ala Val Pro Xaa Pro Asp 
1               5                   


<210>  36
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  36

Arg Arg His Ser Ala Pro Xaa Pro Asp 
1               5                   


<210>  37
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  37

Arg Arg His Ser Val Ala Xaa Pro Asp 
1               5                   


<210>  38
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  38

Arg Arg His Ser Val Pro Ala Pro Asp 
1               5                   


<210>  39
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  39

Arg Arg His Ser Val Pro Xaa Ala Asp 
1               5                   


<210>  40
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  40

Arg Arg His Ser Val Pro Xaa Pro Ala 
1               5                   


<210>  41
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Threonine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  41

Arg Arg His Ser Thr Pro Xaa Pro Asp 
1               5                   


<210>  42
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  42

Asp Gly Glu Ala 
1               


<210>  43
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  ornithine (Orn)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  43

Arg Arg His Ser Val Pro Xaa Pro Asp 
1               5                   


<210>  44
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Valine

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  44

Arg Arg His Ser Val Pro Lys Pro Asp 
1               5                   


<210>  45
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D- Serine

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  45

Arg Arg His Ser Ser Pro Xaa Pro Asp 
1               5                   


<210>  46
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  MYRISTATE group conjugated

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  FITC labeled

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  X is  Diaminobutyric Acid (DAB)

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  C-terminal amidation

<400>  46

Arg Arg His Ser Lys Pro Xaa Pro Asp 
1               5                   


<210>  47
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X is absent or selected from any aino acid residue

<400>  47

Arg Gly Asp Xaa 
1               


<210>  48
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  48

Gly Arg Gly Asp Ser 
1               5   


<210>  49
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  49

Arg Gly Asp Ser 
1               


<210>  50
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  50

Lys Gln Ala Gly Asp Val 
1               5       


<210>  51
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  51

Tyr Ile Gly Ser Arg 
1               5   


<210>  52
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  52

Arg Glu Asp Val 
1               


<210>  53
<211>  15
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  53

Gly Thr Pro Gly Pro Gln Gly Ile Ala Gly Gln Arg Gly Val Val 
1               5                   10                  15  


<210>  54
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  54

Pro Asp Gly Glu Ala 
1               5   


<210>  55
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  55

Ile Lys Val Ala Val 
1               5   


<210>  56
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  56

Arg Asn Ile Ala Glu Ile Ile Lys Asp Ile 
1               5                   10  


<210>  57
<211>  10
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  57

Lys His Ile Phe Ser Asp Asp Ser Ser Glu 
1               5                   10  


<210>  58
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  58

Val Pro Gly Ile Gly 
1               5   


<210>  59
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  59

Phe His Arg Arg Ile Lys Ala 
1               5           


<210>  60
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  60

Lys Arg Ser Arg 
1               


<210>  61
<211>  13
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  61

Lys Phe Ala Lys Leu Ala Ala Arg Leu Tyr Arg Lys Ala 
1               5                   10              


<210>  62
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  62

Lys His Lys Gly Arg Asp Val Ile Leu Lys Lys Asp Val Arg 
1               5                   10                  


<210>  63
<211>  8
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  63

Tyr Lys Lys Ile Ile Lys Lys Leu 
1               5               


<210>  64
<211>  19
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  64

Asn Ser Pro Val Asn Ser Lys Ile Pro Lys Ala Cys Cys Val Pro Thr 
1               5                   10                  15      


Glu Leu Ser 
            


<210>  65
<211>  6
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  65

Ala Ile Ala Pro Gly Leu 
1               5       


<210>  66
<211>  4
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  X is absent or is selected form any amino acid residue

<400>  66

Val Arg Asn Xaa 
1               


<210>  67
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  67

Ala Ala Ala Ala Ala Ala Ala Ala Ala 
1               5                   


<210>  68
<211>  7
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Acetyl group conjugated

<400>  68

Gly Cys Arg Asp Gly Pro Gln 
1               5           


<210>  69
<211>  9
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  69

Gly Ile Trp Gly Gln Asp Arg Cys Gly 
1               5                   


<210>  70
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetetic peptide

<400>  70

Pro Asp Gly Glu Asp 
1               5   


<210>  71
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  LIPID
<222>  (1)..(1)
<223>  a fatty acid residue comprising 16 to 19 carbon atoms attached to
       the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  selected from D-Valine (v), L-Lysine (K) and D-Lysine (k)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  selected from L-Proline (P), D-Proline (p), di amino butyric acid
       (Dab), Di-methyl proline (Dmp), 
       4-tetrahydroisoquinoline-3-carboxylic acid (Tic), 
       (S)-(-)-Indoline-2-carboxylic acid (Idc), Pipecolic acid (Pip), 
       

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Dbu

<220>
<221>  MOD_RES
<222>  (9)..(9)
<223>  an unmodified C-terminus; an amidated C-terminus, connected to a 
       side chain of an amino acid residue to form a cyclic peptide; or 
       connected to a targeting moiety

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be any naturally occurring amino acid

<400>  71

Arg Arg His Ser Xaa Xaa Xaa Pro Asp Xaa 
1               5                   10  


<210>  72
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  LIPID
<222>  (1)..(1)
<223>  a fatty acid residue comprising 16 to 19 carbon atoms

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  selected from D-Valine (v), L-Lysine (K) and D-Lysine (k)

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  selected from: D-Proline (p), di amino butyric acid (Dab), 
       Di-methyl proline (Dmp), 4-tetrahydroisoquinoline-3-carboxylic 
       acid (Tic), (S)-(-)-Indoline-2-carboxylic acid (Idc), Pipecolic 
       acid (Pip), and octahydroindolecarboxylic acid (Oic)

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Dbu

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  an unmodified C-terminus; an amidated C-terminus, connected to a 
       side chain of an amino acid residue to form a cyclic peptide; or 
       connected to a targeting moiety

<220>
<221>  misc_feature
<222>  (10)..(10)
<223>  Xaa can be any naturally occurring amino acid

<400>  72

Arg Arg His Ser Xaa Xaa Xaa Pro Asp Xaa 
1               5                   10  


<210>  73
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic peptide


<220>
<221>  LIPID
<222>  (1)..(1)
<223>  a fatty acid residue comprising at least 16 carbon atoms

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  D-Lysine (k) or L-Lysine (K)

<220>
<221>  MISC_FEATURE
<222>  (5)..(9)
<223>  Cyclization between the side chain of the Lysine or D-Lysine 
       residue and the carboxy terminus

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  D-Proline (p) or L-Proline (P)

<220>
<221>  MOD_RES
<222>  (7)..(7)
<223>  Dbu

<400>  73

Arg Arg His Ser Xaa Xaa Xaa Pro Asp 
1               5                   


